SLNCF — Silence Therapeutics Balance Sheet
0.000.00%
- $134.59m
- -$12.74m
- $43.26m
Annual balance sheet for Silence Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | 10-K | 10-K |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | fx Final | fx Final | fx Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 51.2 | 99.5 | 86.1 | 68.8 | 147 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 45.8 | 11.5 | 21 | 24 | 26.9 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 104 | 117 | 117 | 103 | 187 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.54 | 2.63 | 2.66 | 2.31 | 1.98 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 118 | 130 | 130 | 119 | 203 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 35 | 20.5 | 26.2 | 22.3 | 16.8 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 105 | 119 | 103 | 97.5 | 68.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 12.4 | 11.5 | 26.7 | 22 | 134 |
Total Liabilities & Shareholders' Equity | 118 | 130 | 130 | 119 | 203 |
Total Common Shares Outstanding |